(Reuters) -AbbVie said on Thursday its drug met the main goal in a late-stage trial when tested in patients with early Parkinson’s disease.
The trial studied two doses of the drug, tavapadon, as a monotherapy in which patients showed a statistically significant improvement when compared to placebo, as measured on a rating scale that evaluates various aspects of the disease.
Tavapadon is being studied as a once-daily treatment for Parkinson’s disease – a movement disorder of the nervous system which worsens over time.
AbbVie (NYSE:) gained access to the treatment with its $8.7 billion buyout of Cerevel Therapeutics.
